http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2764216-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_78379d6a77d07f653b68dea87e1f4758 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-573 |
| filingDate | 2020-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fcadca1037c7e1796c3b2bf2f9be2503 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5f579d4ec7b473c6ced789ab19183a1a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd571ddb5bae887ed8a2f16fa6f0c880 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29e4fdd6ba2604687e178ac5e739d40c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f42eaadc77b400c32ea91b67a86e1ce9 |
| publicationDate | 2022-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2764216-C1 |
| titleOfInvention | Method for treating glomerulonephrites with nephrotic syndrome with a relapsing course |
| abstract | FIELD: medicine.SUBSTANCE: invention relates to the field of medicine and pharmaceuticals, namely, to a method for treating glomerulonephrites with nephrotic syndrome with a relapsing course. The method includes introduction of an immunomodulator – recombinant interleukin-2 (rIL-2) and a corticosteroid – prednisolone during the nephrotic syndrome, wherein rIL-2 is prescribed at a dose of 500,000 units subcutaneously 3 times at intervals of 7 days quarterly in addition to prednisolone and the intake is terminated upon reaching the cumulative dose, and treatment with prednisolone is prescribed orally in stages, at the first stage in the first 28 days at a dose of 0.75 to 1 mg/kg per day, from day 29, prednisolone is prescribed in an alternating mode at an initial dose of 1.5 to 2 mg/kg every other day with a consecutive reduction in the dose of 5, 2.5, 1.25 and 0.625 mg per week to a maintaining dose of 2.5 mg.EFFECT: invention provides an increase in the effectiveness of treatment of recurrent glomerulonephritis with nephrotic syndrome due to the introduction of rIL-2 into the body in small, empirically selected doses, wherein the doses do not cause autoimmune inflammation in the renal glomeruli, a reduction in the frequency of relapses of the disease, inhibition of the progression of the disease, a reduction in the possibility of developing dangerous adverse reactions.1 cl, 4 tbl, 3 ex |
| priorityDate | 2020-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 108.